Evaluation of Multiple Potential Pharmacogenomic Risk Factors for Chronic Mefloquine Neurotoxicity through the Establishment of a Drug Safety Registry

Abstract

The purpose of this study is to investigate possible pharmacogenomic risk factors for mefloquine neurotoxicity and potentially find markers that may differentiate between mefloquine toxicity and PTSD. This study is a pilot study powered to find large, clinically significant differences in genetic variants along with exploratory objectives aimed at looking for trends in symptom complexes, environmental interactions with various genetic markers and differences between mefloquine toxicity and PTSD. The subject population includes anyone with a mefloquine exposure history or diagnosis of PTSD without mefloquine exposure. The study is a cross-sectional case-control study. The protocol has been approved by the USUHS IRB and the business contract is currently being reviewed.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jun 01, 2020
Accession Number
AD1105503

Entities

People

  • Jeffrey R. Livezey
  • Thomas G. Oliver

Organizations

  • Uniformed Services University of the Health Sciences

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Anxiety Disorders
  • Biomedical Research
  • Commerce
  • Contracts
  • Data Analysis
  • Department Of Defense
  • Diseases And Disorders
  • Electronic Mail
  • Genetic Markers
  • Patent Applications
  • Pilot Studies
  • Professional Development
  • Risk Factors
  • Technology Transfer
  • Test And Evaluation
  • Toxicity
  • Traumatic Stress Disorder

Readers

  • Manufacturing Engineering.
  • Neurotoxicology
  • Psychological Intervention/Treatment for Stress, Anxiety, PTSD, and Related Emotional and Cognitive Health Symptoms.

Technology Areas

  • Biotechnology